To access Scientific Presentations Archive,
click here.
Rigosertib Demonstrates Considerable Efficacy and Safety in the Treatment of Advanced/Metastatic Cutaneous Squamous Cell Carcinoma in Patients with Recessive Dystrophic Epidermolysis Bullosa
Rigosertib Demonstrates Considerable Efficacy and Safety in the Treatment of Advanced/Metastatic Cutaneous Squamous Cell Carcinoma in Patients with Recessive Dystrophic Epidermolysis Bullosa
Risk/Benefit Profiles of Currently Approved Oral Antivirals forTreatment of COVID-19: Similarities and Differences
Risk/Benefit Profiles of Currently Approved Oral Antivirals for Treatment of COVID-19: Similarities and Differences
Travatrelvir, an Inhibitor of SARS-CoV-2 Main Protease now in Phase 1 Clinical Trials: in vitroDrug Resistance Compared to Nirmatrelvir
Travatrelvir, an Inhibitor of SARS-CoV-2 Main Protease now in Phase 1 Clinical Trials: in vitro Drug Resistance Compared to Nirmatrelvir